New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $24 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s life cycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 250 portfolio company IPOs and more than 425 mergers and acquisitions.

Pappas Capital invests exclusively in the life science sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. We operate three lines of business: Pappas Ventures, our flagship venture arm; Specialized Fund Management, where we create and manage custom-tailored investment vehicles; and Translational Medicine, where we partner with research universities to accelerate the development of their scientific discoveries and inventions.

Biovision Ventures is a specialised life sciences VC investing in early-stage United States and European companies with a mission to translate groundbreaking science into transformative therapies. We are agnostic about diseases and modalities, but prioritise companies developing therapeutic assets with good IP protection addressing unmet clinical needs.